Results 1 - 10 of 26 : 1 2 3 Next
ZymoGenetics Leads With Its Chin
What does it tell us when talk about a drug still in development takes top billing over sales of an approved drug?
Who's fallen hardest? Who can bounce highest?
King's Unstoppable Urge to Merge
Your potential acquisition isn't interested? Go for the hostile takeover!
It found a way to sell stuff it used to throw away.
See what the best CAPS players recommend now.
If Johnson & Johnson sells its wound-care business, its partner could lose big.
5 Stocks With Hot June Returns
These stocks are tops in the month of June.
Revenue growth is most important for high-growth companies.
So far in 2008, the agency's given more drugs a thumbs-up.
A Fool peers in through Wall Street's out door.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK